Genitourinary Cancers

An analysis of treatment patterns found that patients with advanced urinary tract cancer who are eligible for cisplatin-based chemotherapy fare better when they do receive such regimens than when they do not, highlighting the importance of following published treatment criteria.

Combination treatment with a novel CXCR4 inhibitor and axitinib resulted in an encouraging overall response rate and disease control rate in patients with clear cell renal cell carcinoma, according to the results from phase I of a phase I/II trial.

In this interview we discuss the STOPCaP trial, a meta-analysis that looked at optimal systemic therapy options for men with metastatic hormone-sensitive prostate cancer.

Patients with upper tract urothelial carcinoma who do not undergo definitive therapy have poorer outcomes than those who do, according to a new study.

Cabozantinib reduced the risk for disease progression or death by 52% compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to updated results from the CABOSUN trial.

This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.

Treatment with pazopanib 600 mg had no benefit over placebo for patients who had undergone nephrectomy for localized or locally advanced renal cell carcinoma.

The presence of more comorbidities had an effect on all-cause mortality, but not prostate cancer-specific mortality, in a large cohort study of men with prostate cancer.

TRC105, a monoclonal antibody against endoglin, failed to improve progression-free survival when added to bevacizumab compared with bevacizumab alone in patients with refractory metastatic renal cell carcinoma.

The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.

The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.

More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.

The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.

An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.

Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease.

African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients.

Immediate treatment with androgen-deprivation therapy for men with asymptomatic non-curable prostate cancer did not have major effects on quality of life compared with delayed use, according to a phase III trial.

Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer.

Men with non-metastatic prostate cancer who receive androgen deprivation therapy risk loss of bone mineral density and fractures, but both bisphosphonates and denosumab can improve their bone health.

In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study.

Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study.

Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab.

An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non–muscle-invasive bladder cancer (NMIBC).

Taller men are at increased risk for high-grade prostate cancer and prostate cancer death, according to a large registry study. Greater adiposity is also associated with higher-grade tumors and mortality.

Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.

RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.

A urine test of telomerase reverse transcriptase (TERT) was found to be a reliable predictor of recurrence in non–muscle-invasive bladder cancer, according to a new study.

A phase II study has shown that savolitinib is active in a subgroup of patients with papillary renal cell carcinoma with gene amplification or mutations in the MET pathway.

Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.

After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.